Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
McKesson
Johnson and Johnson
Medtronic

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for GS-5745


Email this page to a colleague

« Back to Dashboard

What is the drug development status for GS-5745?

GS-5745 is an investigational drug.

There have been 11 clinical trials for GS-5745. The most recent clinical trial was a Phase 3 trial, which was initiated on October 13th 2015.

The most common disease conditions in clinical trials are Adenocarcinoma, Esophageal Neoplasms, and Colitis, Ulcerative. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].

There are four US patents protecting this investigational drug and nine international patents.

Recent Clinical Trials for GS-5745
TitleSponsorPhase
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisGilead SciencesPhase 2
Effect of Andecaliximab on FEV1 in Adults With Cystic FibrosisGilead SciencesPhase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction AdenocarcinomaGilead SciencesPhase 1

See all GS-5745 clinical trials

Clinical Trial Summary for GS-5745

Top disease conditions for GS-5745
Top clinical trial sponsors for GS-5745

See all GS-5745 clinical trials

US Patents for GS-5745

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-5745 ⤷  Try it Free Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. (South San Francisco, CA) ⤷  Try it Free
GS-5745 ⤷  Try it Free Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. (South San Francisco, CA) ⤷  Try it Free
GS-5745 ⤷  Try it Free Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation (Wilmington, DE) ⤷  Try it Free
GS-5745 ⤷  Try it Free Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation (Wilmington, DE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-5745

Drugname Country Document Number Estimated Expiration Related US Patent
GS-5745 China CN108349996 2035-09-08 ⤷  Try it Free
GS-5745 China CN112409378 2035-09-08 ⤷  Try it Free
GS-5745 European Patent Office EP3347361 2035-09-08 ⤷  Try it Free
GS-5745 Hong Kong HK1258849 2035-09-08 ⤷  Try it Free
GS-5745 Japan JP2018526393 2035-09-08 ⤷  Try it Free
GS-5745 Japan JP2021088559 2035-09-08 ⤷  Try it Free
GS-5745 Japan JP6873977 2035-09-08 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
McKesson
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.